China Resources Pharmaceutical Group Limited (HKG:3320)
5.24
+0.03 (0.58%)
Apr 29, 2026, 4:08 PM HKT
HKG:3320 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | - | 3,351 | 3,854 | 3,500 | 3,070 | Upgrade
|
| Depreciation & Amortization | - | 3,357 | 3,164 | 2,558 | 2,299 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -70.12 | -63.85 | -334.84 | -7.83 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 1,534 | 1,161 | 1,101 | 216.24 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -79.89 | 21.34 | -17.41 | -101.66 | Upgrade
|
| Loss (Gain) on Equity Investments | - | -368.01 | -417.11 | -332.34 | -255.48 | Upgrade
|
| Stock-Based Compensation | - | 78.32 | 141.89 | 99.55 | 1.17 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 263.8 | 450.67 | 478.75 | 371.34 | Upgrade
|
| Other Operating Activities | - | 6,637 | 5,636 | 4,369 | 4,625 | Upgrade
|
| Change in Accounts Receivable | - | -6,914 | -6,077 | -6,441 | -3,851 | Upgrade
|
| Change in Inventory | - | -4,940 | -2,668 | -2,233 | -2,779 | Upgrade
|
| Change in Accounts Payable | - | 14,435 | 10,910 | 8,109 | 6,140 | Upgrade
|
| Change in Unearned Revenue | - | 201.66 | 279.44 | 704.95 | 728.41 | Upgrade
|
| Change in Other Net Operating Assets | - | 50.82 | -842.7 | -741.93 | 6.25 | Upgrade
|
| Operating Cash Flow | - | 17,536 | 15,550 | 10,821 | 10,462 | Upgrade
|
| Operating Cash Flow Growth | - | 12.77% | 43.70% | 3.43% | 51.41% | Upgrade
|
| Capital Expenditures | - | -2,645 | -2,523 | -2,279 | -1,967 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 181.83 | 176.95 | 73.05 | 117.08 | Upgrade
|
| Cash Acquisitions | - | -1,863 | 646.53 | - | -1,415 | Upgrade
|
| Divestitures | - | -2.87 | 39.85 | 422.15 | 190.72 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -430.91 | -476.91 | -302.51 | -490.28 | Upgrade
|
| Investment in Securities | - | -4,793 | -528.52 | 267.68 | -4,007 | Upgrade
|
| Other Investing Activities | - | 664.17 | 598.05 | 999.86 | 84.22 | Upgrade
|
| Investing Cash Flow | - | -8,888 | -2,067 | -819.24 | -7,487 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 2,304 | 2,056 | Upgrade
|
| Long-Term Debt Issued | - | 79,744 | 85,184 | 88,175 | 74,444 | Upgrade
|
| Total Debt Issued | - | 79,744 | 85,184 | 90,479 | 76,500 | Upgrade
|
| Short-Term Debt Repaid | - | -2,993 | -5,213 | - | -1,794 | Upgrade
|
| Long-Term Debt Repaid | - | -83,422 | -82,426 | -93,884 | -69,769 | Upgrade
|
| Total Debt Repaid | - | -86,415 | -87,639 | -93,884 | -71,563 | Upgrade
|
| Net Debt Issued (Repaid) | - | -6,671 | -2,455 | -3,405 | 4,937 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -3,018 | - | Upgrade
|
| Common Dividends Paid | - | -1,489 | -879.97 | -813.07 | -614.18 | Upgrade
|
| Other Financing Activities | - | -8,679 | -730.22 | -1,890 | -1,875 | Upgrade
|
| Financing Cash Flow | - | -16,838 | -4,065 | -9,126 | 2,448 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -35.22 | 9.66 | 31.92 | -295.47 | Upgrade
|
| Net Cash Flow | - | -8,226 | 9,427 | 907.75 | 5,128 | Upgrade
|
| Free Cash Flow | - | 14,891 | 13,027 | 8,542 | 8,495 | Upgrade
|
| Free Cash Flow Growth | - | 14.31% | 52.51% | 0.55% | 54.34% | Upgrade
|
| Free Cash Flow Margin | - | 5.78% | 5.32% | 3.91% | 4.40% | Upgrade
|
| Free Cash Flow Per Share | - | 2.37 | 2.07 | 1.36 | 1.35 | Upgrade
|
| Cash Interest Paid | - | 2,102 | 2,644 | 1,937 | 2,164 | Upgrade
|
| Cash Income Tax Paid | - | 2,633 | 2,307 | 2,222 | 1,640 | Upgrade
|
| Levered Free Cash Flow | - | -8,585 | 1,759 | 8,338 | -2,434 | Upgrade
|
| Unlevered Free Cash Flow | - | -7,172 | 3,235 | 9,855 | -1,053 | Upgrade
|
| Change in Working Capital | - | 2,833 | 1,601 | -601.92 | 244.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.